Therapeuticdiscovery
Biosimilar Bevacizumab
Originator: Avastin (Genentech/Roche)
Biosimilar program of Bevacizumab (Avastin), an anti-VEGF monoclonal antibody used in multiple solid tumour indications.
Indications
- Metastatic colorectal cancer
- Non-small cell lung cancer
- Renal cell carcinoma
- Glioblastoma
- Cervical cancer
- Ovarian cancer
Overview
Bevacizumab (originator: Avastin) targets vascular endothelial growth factor (VEGF). IMGENEX India is developing a biosimilar version using its CHO mammalian expression platform with the goal of dramatically improving patient access in emerging markets.
Contact us today to learn more about this product. You can also email us at info@imgenexindia.com.